{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:46:08Z","timestamp":1791380768726,"version":"4.3.3"},"reference-count":17,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Buprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of buprenorphine withdrawal psychosis, yet all of them were male. In this case report, we present a 41-year-old female patient with bipolar disorder and comorbid substance use disorder who developed new-onset psychosis and relapse of manic symptoms following abrupt discontinuation of Suboxone. Manic and psychotic symptoms remitted after a short-term hospitalization with the treatment of an antipsychotic and a mood stabilizer. In addition to discussing this case presentation and treatment approach, we review existing literature and discuss possible underlying mechanisms to enhance understanding of this clinical phenomenon.<\/jats:p>","DOI":"10.64719\/pb.4446","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"72-80","source":"Crossref","is-referenced-by-count":1,"title":["New-Onset Psychotic Symptoms Following Abrupt Buprenorphine\/ Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report"],"prefix":"10.64719","volume":"52","author":[{"given":"Yezhe","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin B","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Trestman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita S","family":"Kablinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in US adults: 2015 National Survey on Drug Use and Health. Annals of internal medicine. 2017;167:293\u2013301.","DOI":"10.7326\/M17-0865"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 2016;162:190\u2013198.","DOI":"10.1016\/j.drugalcdep.2016.03.005"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000;61:85\u201394.","DOI":"10.1016\/S0376-8716(00)00126-5"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Elkader A, Sproule B. Buprenorphine. Clinical Pharmacokinetics. 2005;44:661\u2013680.","DOI":"10.2165\/00003088-200544070-00001"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Annals of the new York Academy of Sciences. 1982;398:108\u2013112.","DOI":"10.1111\/j.1749-6632.1982.tb39483.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Jagadheesan K, Muirhead D. Possible manic potential of buprenorphine. The Australian and New Zealand journal of psychiatry. 2004;38:560\u2013561.","DOI":"10.1111\/j.1440-1614.2004.01411.x"},{"key":"ref7","unstructured":"Lozano-Lopez MT, Gamonal-Limcaoco S, Casado-Espada N, Aguilar L, Vicente-Hernandez B, Grau-Lopez L, Alvarez-Navares A, Roncero C. Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review. Eur Rev Med Pharmacol Sci. 2021;25:4554\u20134562."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Navkhare P, Kalra G, Saddichha S. Possible Psychosis Associated With Buprenorphine Withdrawal. J Clin Psychopharmacol. 2017;37:748\u2013749.","DOI":"10.1097\/JCP.0000000000000803"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Weibel S, Mallaret M, Bennouna-Greene M, Bertschy G. A case of acute psychosis after buprenorphine withdrawal: abrupt versus progressive discontinuation could make a difference. J Clin Psychiatry. 2012;73:0\u20130.","DOI":"10.4088\/JCP.11cr07608"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Karila L, Berlin I, Benyamina A, Reynaud M. Psychotic symptoms following buprenorphine withdrawal. Am J Psychiatry. 2008;165:400\u2013401.","DOI":"10.1176\/appi.ajp.2007.07071103"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u2013435.","DOI":"10.1192\/bjp.133.5.429"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lukasiewicz M, Gerard S, Besnard A, Falissard B, Perrin E, Sapin H, Tohen M, Reed C, Azorin J-M. Emblem Study Group. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. International Journal of Methods in Psychiatric Research. 2013;22:46\u201358.","DOI":"10.1002\/mpr.1379"},{"key":"ref13","unstructured":"Organization, World Health. Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Setting. Geneva, Switzerland. 2009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Sullivan SA, Kounali D, Cannon M, David AS, Fletcher PC, Holmans P, Jones H, Jones PB, Linden DEJ, Lewis G. A population-based cohort study examining the incidence and impact of psychotic experiences from childhood to adulthood, and prediction of psychotic disorder. American Journal of Psychiatry. 2020;177:308\u2013317.","DOI":"10.1176\/appi.ajp.2019.19060654"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res. 2018;194:78\u201385.","DOI":"10.1016\/j.schres.2017.04.016"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Li KJ, Chen A, DeLisi LE. Opioid use and schizophrenia. Curr Opin Psychiatry. 2020;33:219\u2013224.","DOI":"10.1097\/YCO.0000000000000593"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Schmauss C, Yassouridis A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340\u20131342.","DOI":"10.1176\/ajp.144.10.1340"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:31:14Z","timestamp":1791315074000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/new-onset-psychotic-symptoms-following-abrupt-buprenorphine-naloxone-discontinuation-in-a-female-patient-with-bipolar-disorder-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4446","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}